Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus chemotherapy as a standard-of-care option based on improved pathologic response and event-free survival outcomes.
Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic therapy focused on disease control and survival in advanced stages.
Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.
Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.
This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.
Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.
Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.
Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.
Experts discuss the challenges of integrating new cancer therapies, addressing multidisciplinary care, evolving guidelines, and the financial burden on patients.
Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.
Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.
Nurse navigators play a crucial role in managing HER2-targeted therapy side effects, ensuring patient education and early toxicity detection.
Explore the safety considerations and unique toxicities of bispecific antibodies, including cytokine release syndrome and neurotoxicity management.
Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.
Data at ASH 2025 highlighted that standardized workflows, education, monitoring innovations, and collaboration are steadily enabling broader, safer adoption of bispecific antibodies in community oncology practice.
ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, and the growing need to define when therapy can be safely de-escalated or stopped in multiple myeloma.
ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and logistical barriers, provided toxicity remains manageable.
ASH 2025 data emphasize that standardized protocols and strong academic-community communication are essential for safe and consistent management of bispecific antibody adverse events in community oncology.
Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.
Explore how evolving treatment strategies and biomarkers are transforming the management of HER2-positive breast cancer in clinical practice.
Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.
It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising important questions about durability, safety, and patient selection.
Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune therapies—paired with MRD monitoring and intensified maintenance strategies—is redefining outcomes in mantle cell lymphoma.
Remote patient monitoring can safely enable outpatient bispecific dosing for selected patients, but older or high-risk individuals may still require closer human oversight and structured support.
Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug resistance in mantle cell lymphoma through epigenetic profiling and the biology of drug-tolerant persister cells.
Combining complementary targeted therapies for multiple myeloma has shown impressive efficacy, but safety, quality of life, and costs must also be considered.
Data suggest that remote patient monitoring may support outpatient step-up dosing of bispecific antibodies by enabling earlier CRS detection.
